Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: Effects on insulin-resistance, leptin and tumor necrosis factor-α

Hypertension Research

Volumn 29, Issue 11, 2006, Pages 849-856

  Derosa, Giuseppe ^a   Cicero, Arrigo F G ^b   D'Angelo, Angela ^a   Ragonesi, Pietro D ^c   Ciccarelli, Leonardina ^a   Piccinni, Mario N ^a   Pricolo, Fabio ^a   Salvadeo, Sibilla A T ^a   Ferrari, ILaria ^a   Gravina, Alessia ^a   Fogari, Roberto ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c SAN CARLO BORROMEO HOSPITAL   (Italy)

Author keywords

Irbesartan; Metabolic syndrome; Rosiglitazone; Telmisartan; Type 2 diabetes

Indexed keywords

ACARBOSE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; CHOLESTEROL; FLUINDOSTATIN; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; IRBESARTAN; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PRAVASTATIN; REPAGLINIDE; ROSIGLITAZONE; ROSUVASTATIN; SIMVASTATIN; TELMISARTAN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BODY MASS; CALORIC RESTRICTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC DIET; DIASTOLIC BLOOD PRESSURE; DISEASE CONTROL; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG CHOICE; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; ITALY; KINESIOTHERAPY; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; METABOLIC SYNDROME X; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; BENZOATES; BIPHENYL COMPOUNDS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LEPTIN; LIPIDS; MALE; MIDDLE AGED; TETRAZOLES; THIAZOLIDINEDIONES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33846087364     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.29.849     Document Type: Article

References (39)

1. American Diabetes Association: Hypertension management in adults with diabetes. Diabetes Care 2004; 27 (Suppl 1): 65-67.
2. Adler AI: Treating high blood pressure in diabetes: the evidence. Semin Vasc Med 2002; 2: 127-137.
3. Ruilope LM, Rosei EA, Bakris GL, et al: Angiotensin receptor blockers: therapeutic targets and cardiovascular protection. Blood Press 2005; 14: 196-209.
4. 1-receptor blockers: differences that matter. J Hum Hypertens 2002; 16 (Suppl 3): S90-S16.
5. Pylypchuk GB: ACE inhibitor - versus angiotensin II blocker - induced cough and angioedema. Ann Pharmacother 1998; 32: 1060-1066.
6. Sica DA, Bakris GL: Type 2 diabetes: RENAAL and IDNT - the emergence of new treatment options. J Clin Hypertens 2002; 4: 52-57.
7. American Diabetes Association, National Institute of Diabetes and Digestive and Kidney Diseases: Prevention or delay of type 2 diabetes. Diabetes Care 2004; 27 (Suppl 1): 47-54.
8. Schupp M, Clemenz M, Gineste R, et al: Molecular characterization of new selective peroxisome proliferator-activated receptor γ modulators with angiotensin receptor blocking activity. Diabetes 2005; 54: 3442-3452.
9. American Diabetes Association: Screening for diabetes (Position Statement). Diabetes Care 2001; 24 (Suppl): S21-S24.
10. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
11. Guidelines Subcommittee: 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999; 17: 151-183.
12. World Health Organization: Obesity: Preventing and Managing the Global Epidemic, Report of WHO Consultation on Obesity. Geneva, WHO, 1997.
13. American Diabetes Association: Nutrition recommendations and principles for people with diabetes mellitus (Position Statement). Diabetes Care 2001; 24 (Suppl): S44-S47.
14. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
15. Bunn HF, Gabbay KH, Gallop PM: The glycosylation of haemoglobin. Relevance to diabetes mellitus. Science 1978; 200: 21-27.
16. European Diabetes Policy Group 1999: A desktop guide to type 2 diabetes mellitus. Diabet Med 1999; 16: 716-730.
17. Heding LG: Determination of total serum insulin (IRI) in insulin-treated diabetic patients. Diabetologia 1972; 8: 260-266.
18. Klose S, Borner K: Enzymatische Bestimmung des Gesamtcholesterins mit dem (Enzymatic dosage of total cholesterolemia by Greiner Selective Analyzer [GSA II]). J Clin Chem Clin Biochem 1978; 15: 121-130.
19. Wahlefeld AW: Triglycerides determination after enzymatic hydrolysis, in Bergmeyer HU (ed): Methods of Enzymatic Analysis, 2nd English ed. New York, Academic Press, 1974, pp 18-31.
20. Havel RJ, Eder HA, Bragdon JH: The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955; 34: 1345-1353.
21. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low density lipoprotein in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
22. Zhang M, Tracey K: The Cytokine Handbook, 3rd ed. San Diego, Academic Press, 1988.
23. Misra A, Garg A: Leptin: its receptor and obesity. J Invest Med 1996; 44: 540-548.
24. Winer BJ: Statistical Principles in Experimental Design, 2nd ed. New York, McGraw-Hill, 1971.
25. Skrha J, Ambos A: Can the atherosclerosis prevention targets be achieved in type 2 diabetes? Diabetes Res Clin Pract 2005; 68 (Suppl 1): S48-S51.
26. Barnett AH: Preventing renal complications in diabetic patients: the Diabetics Exposed to Telmisartan and Enalapril (DETAIL) study. Acta Diabetol 2005; 42 (Suppl 1): S42-S49.
27. Miura Y, Yamamoto N, Tsunekawa S, et al: Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences. Diabetes Care 2005; 28: 757-758.
28. Bramlage P, Pittrow D, Kirch W: The effect of irbesartan in reducing cardiovascular risk in hypertensive type 2 diabetic patients: an observational study in 16,600 patients in primary care. Curr Med Res Opin 2004; 20: 1625-1631.
29. Ravera M, Ratto E, Vettoretti S, Parodi D, Deferrari G: Prevention and treatment of diabetic nephropathy: the program for irbesartan mortality and morbidity evaluation. J Am Soc Nephrol 2005; 16 (Suppl 1): S48-S52.
30. Derosa G, Cicero AF, Gaddi A, Mugellini A, Ciccarelli L, Fogari R: Effects of doxazosin and irbesartan on blood pressure and metabolic control in patients with type 2 diabetes and hypertension. J Cardiovasc Pharmacol 2005; 45: 599-604.
31. Derosa G, Ragonesi PD, Mugellini A, Ciccarelli L, Fogari R: Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensioe, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study. Hypertens Res 2004; 27: 457-464.
32. Derosa G, Cicero AFG, Bertone G, et al: Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and a 12-month, randomized, double-blind study. Clin Ther 2004; 26: 1228-1236.
33. Derosa G, Cicero AFG, Gaddi A, et al: Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve month, multicenter, double-blind, randomized, controlled, parallel-group trial. Clin Ther 2004; 26: 744-754.
34. Derosa G, Cicero AFG, Gaddi AV, et al: Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial. Clin Ther 2005; 27: 1383-1391.
35. Clasen R, Schupp M, Foryst-Ludwig A, et al: PPAR-gamma-activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension 2005; 46: 137-143.
36. Tsuchida A, Yamauchi T, Takekawa S, et al: Peroxisome proliferator-activated receptor (PPAR) α activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPARα, PPARγ, and their combination. Diabetes 2005; 54: 3358-3370.
37. Berger JP, Petro AE, Macnaul KL, et al: Distinct properties and advantages of a novel peroxisome proliferators-activated protein (gamma) selective modulator. Mol Endocrinol 2003; 17: 662-676.
38. Wang M, Tafuri S: Modulation of PPARgamma activity with pharmaceutical agents: treatment of insulin resistance and atherosclerosis. J Cell Biochem 2003; 89: 38-47.
39. Guan HP, Ishizuka T, Chui PC, Lehrke M, Lazar MA: Corepressors selectively control the transcriptional activity of PPARgamma in adipocytes. Gene Dev 2005; 19: 453-461.